NextGen Healthcare Overview
Valuation check: NXGN's ROE is -1.47%, below the Technology sector average of 47.61%.
Get informed when a big investor buys or sells
+ Follow-1.47%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
NextGen Healthcare posts a ROE of -1.47%. That is below the Technology sector average of 47.61%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Technology stocks, a ROE near 47.61% is typical. NextGen Healthcare's -1.47% is lower that level. That is roughly 103.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
NextGen Healthcare's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -1.47%; use YoY and peer views to separate noise from signal.
Context for NXGN's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 47.61%), and (3) consistency with growth and profitability. This page covers the first two; NextGen Healthcare's other metric pages and overview cover the third.
Judging NextGen Healthcare against Technology peers is usually better than using a market-wide rule of thumb. Business models inside Technology are more comparable, which makes gaps in ROE easier to interpret. Start with -1.47% here, then scan peer and history charts to see if the gap is persistent.
